Scientists test 'Kick and Kill' combo in bold bid for HIV remission
NCT ID NCT06484335
Summary
This early-stage study is testing a two-part strategy to help the body control HIV without needing daily antiretroviral therapy (ART). It combines lab-made antibodies with a therapeutic vaccine in people who started treatment very early after infection. The main goals are to see if the combination is safe and if it can keep the virus at a low level when participants temporarily stop their regular HIV medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Faculty of Medicine, Chulalongkorn University/ King Chulalongkorn Memorial Hospital
RECRUITINGPathum Wan, Bangkok, 10330, Thailand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.